Entinostat

Generic Name: Entinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₀N_₄O_₃

CAS Number: 209783-80-2

Unique Ingredient Identifier: 1ZNY4FKK9H

Background: Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.

Indication: 联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。

Clinical Trials

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

Phase 2

Terminated

Conditions: Triple-negative Breast Cancer
HER2-negative Breast Cancer
Stage I Breast Cancer
Stage IIIA Breast Cancer
Estrogen Receptor-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage II Breast Cancer

Interventions: Drug: entinostat
Drug: anastrozole
Other: diagnostic laboratory biomarker analysis
Procedure: therapeutic conventional surgery

First Posted Date: 2010-11-04

Last Posted Date: 2022-05-03

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 5

Registration Number: NCT01234532

Locations: 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Phase 2

Terminated

Conditions: Stage IB Non-Small Cell Lung Carcinoma
Stage IA Non-Small Cell Lung Carcinoma

Interventions: Drug: Azacitidine
Drug: Entinostat
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-09-23

Last Posted Date: 2019-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT01207726

Locations: 🇺🇸
Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 6 locations

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: entinostat
Drug: sorafenib tosylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-07-09

Last Posted Date: 2013-09-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT01159301

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Phase 1

Completed

Conditions: Acute Leukemias of Ambiguous Lineage
Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Lymphoblastic Leukemia

Interventions: Drug: entinostat
Drug: clofarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-05-28

Last Posted Date: 2014-07-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT01132573

Locations: 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 1 locations

Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: entinostat
Drug: azacitidine
Other: laboratory biomarker analysis

First Posted Date: 2010-04-16

Last Posted Date: 2014-08-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT01105377

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 11 locations

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Phase 1

Active, not recruiting

Conditions: Stage III Renal Cell Cancer AJCC v7
Stage IV Renal Cell Cancer AJCC v7
Clear Cell Renal Cell Carcinoma
Metastatic Kidney Carcinoma

Interventions: Biological: Aldesleukin
Procedure: Computed Tomography
Drug: Entinostat
Radiation: Fludeoxyglucose F-18
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Procedure: Positron Emission Tomography

First Posted Date: 2009-12-24

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT01038778

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 1 locations

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Entinostat

First Posted Date: 2009-03-20

Last Posted Date: 2019-10-22

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT00866333

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 3 locations

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Phase 2

Completed

Conditions: ER+ Breast Cancer

Interventions: Drug: Entinostat
Drug: Aromatase Inhibitor (AI) Therapy

First Posted Date: 2009-01-26

Last Posted Date: 2022-06-30

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT00828854

Locations: 🇬🇧
University College London Hospitals, London, United Kingdom
🇬🇧
Christie Hospital, Manchester Breast Centre, Manchester, United Kingdom
🇬🇧
Velindre Hospital - Whitchurch, Cardiff, United Kingdom

and more 3 locations

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: SNDX-275

First Posted Date: 2008-09-17

Last Posted Date: 2022-06-06

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT00754312

Locations: 🇺🇸
Monet Bowling, MD, Indianapolis, Indiana, United States

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Entinostat
Drug: Erlotinib

First Posted Date: 2008-09-10

Last Posted Date: 2023-07-06

Lead Sponsor: Syndax Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT00750698

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Sharp Clinical Oncology Research, San Diego, California, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy